Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Repare Therapeutics Inc (NQ: RPTX ) 3.090 +0.080 (+2.66%) Streaming Delayed Price Updated: 11:58 AM EDT, Aug 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Repare Therapeutics Inc < Previous 1 2 3 Next > Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022 January 07, 2022 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development January 05, 2022 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference January 03, 2022 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors December 21, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Insiders Establish New and Modified Automatic Securities Disposition Plans December 15, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences November 15, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results November 10, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares November 02, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares October 27, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Announces Proposed Public Offering of Common Shares October 27, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference October 18, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 08, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Issues Statement Regarding Inadvertent Issuance of Phase 1/2 TRESR RP-3500 Clinical Trial Abstract by the AACR-NCI-EORTC Virtual International Conference October 07, 2021 From Repare Therapeutics, Inc. Via Business Wire Repare Therapeutics to Present Initial Data from the Phase 1/2 TRESR RP-3500 Clinical Trial at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics September 30, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Appoints Thomas Civik to Its Board and as New Chairman September 07, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference September 02, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results August 12, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Participate at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference June 02, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results May 13, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1 May 03, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference April 13, 2021 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Highlight Program Progress for RP-6306 at Today’s Virtual Investor Day Event April 08, 2021 From Repare Therapeutics Inc. Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.